US 2026/0199389 A1 · STRAIN OF DUGANELLA SP., EXOPOLYSACCHARIDE PRODUCED THEREBY, AND USE

Abstract

A strain of Duganella sp., a polysaccharide produced thereby, and use are provided. The Duganella sp. G3 of the present disclosure has the deposit number of CCTCC NO: M 2024137. The exopolysaccharide TDG3 produced by the strain acts as a TLR4/DC-SIGN dual receptor agonist and significantly reduces body weight upon administration to a subject. The exopolysaccharide TDG3 of the present disclosure may significantly reduce appetite in a subject, decrease food take, lower body weight, and reduce fat mass. It may also alleviate or prevent obesity-induced hepatic steatosis. It is safe and non-toxic, is suitable for use in lipid-lowering and weight-loss drugs, and has good clinical application value and broad application prospects.

Claims8

Dependent claims

A method for culturing Duganella sp. strain. G3 having a deposit number of China Center for Type Culture Collection (CCTCC) NO:

M 2024137, comprising inoculating the Duganella sp. G3 into a fermentation medium for culture, and culturing the resulting inoculated culture at a pH of 5 to 9, and a temperature of 26° C. to 32° C. in a fermentation medium comprising carbon source 20 to 50 g/L, nitrogen source 1 to 4 g/L, NaH2PO4 0.5 to 2 g/L, CaCl2) 0.02 to 0.1 g/L, MgSO4·7H2O 0.1 to 0.5 g/L, FeSO4·7H2O 0.01 to 0.06 g/L, MnSO4·H2O0.005 to 0.01 g/L, and ZnCl2 0.01 to 0.02 g/L.

Dependencies are inferred from the claim text.

Strain of duganella sp., exopolysaccharide produced thereby, and use

Life of this patent

Strain of duganella sp., exopolysaccharide produced thereby, and use

Life of this patent

Abstract

Claims8